 NEW YORK BRISBANE, Calif.--BUSINESS WIRE--Pfizer Inc. NYSE: PFE and Sangamo Therapeutics, Inc. Nasdaq: SGMO, a genomic medicines company, today announced updated follow-up data from the Phase 12 Alta study of giroctocogene fitelparvovec SB-525 or PF-07055480, an investigational gene therapy for patients with severe hemophilia A. These data are being presented today at the 62nd American Society for Hematology Annual meeting taking place virtually from December 5th - 8th. The oral pres 